Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities

The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angi...

Full description

Autores:
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13162
Acceso en línea:
https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!
http://hdl.handle.net/20.500.12010/13162
https://doi.org/10.1016/j.pharmthera.2020.107628
Palabra clave:
RAAS inhibitors
Hypertension
Bradykinin
Inflammation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Acceso restringido
id UTADEO2_d93c78096826749c4f8ae01ea41b73a7
oai_identifier_str oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13162
network_acronym_str UTADEO2
network_name_str Expeditio: repositorio UTadeo
repository_id_str
dc.title.spa.fl_str_mv Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
title Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
spellingShingle Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
RAAS inhibitors
Hypertension
Bradykinin
Inflammation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
title_short Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
title_full Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
title_fullStr Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
title_full_unstemmed Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
title_sort Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
dc.subject.spa.fl_str_mv RAAS inhibitors
Hypertension
Bradykinin
Inflammation
topic RAAS inhibitors
Hypertension
Bradykinin
Inflammation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
dc.subject.lemb.spa.fl_str_mv Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
description The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin–angiotensin–aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-09-11T15:19:29Z
dc.date.available.none.fl_str_mv 2020-09-11T15:19:29Z
dc.date.created.none.fl_str_mv 2020-05-09
dc.type.local.spa.fl_str_mv Artículo
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
format http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.spa.fl_str_mv 0163-7258
dc.identifier.other.spa.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12010/13162
dc.identifier.doi.spa.fl_str_mv https://doi.org/10.1016/j.pharmthera.2020.107628
identifier_str_mv 0163-7258
url https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!
http://hdl.handle.net/20.500.12010/13162
https://doi.org/10.1016/j.pharmthera.2020.107628
dc.language.iso.spa.fl_str_mv eng
language eng
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.local.spa.fl_str_mv Acceso restringido
rights_invalid_str_mv Acceso restringido
http://purl.org/coar/access_right/c_16ec
dc.format.extent.spa.fl_str_mv 9 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Pharmacology & Therapeutics
dc.source.spa.fl_str_mv reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
instname_str Universidad de Bogotá Jorge Tadeo Lozano
institution Universidad de Bogotá Jorge Tadeo Lozano
reponame_str Expeditio Repositorio Institucional UJTL
collection Expeditio Repositorio Institucional UJTL
bitstream.url.fl_str_mv https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/3/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/2/license.txt
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/4/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.png
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/5/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf.jpg
bitstream.checksum.fl_str_mv c54a461b3c942267773842c0f5c220b4
abceeb1c943c50d3343516f9dbfc110f
3c33bd14a529fb237a48e55516cbfa36
76a6e57d702143ef4af5100ab73df7fd
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional - Universidad Jorge Tadeo Lozano
repository.mail.fl_str_mv expeditio@utadeo.edu.co
_version_ 1814213843783516160
spelling 2020-09-11T15:19:29Z2020-09-11T15:19:29Z2020-05-090163-7258https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!http://hdl.handle.net/20.500.12010/13162https://doi.org/10.1016/j.pharmthera.2020.1076289 páginasapplication/pdfengPharmacology & Therapeuticsreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoRAAS inhibitorsHypertensionBradykininInflammationSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusGood or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbiditiesArtículohttp://purl.org/coar/resource_type/c_6501Acceso restringidohttp://purl.org/coar/access_right/c_16ecThe coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin–angiotensin–aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful.Wang, James JiqiEdin, Matthew L.Zeldin, Darryl C.Li, ChenzeWang, Dao WenChen, ChenORIGINALGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdfGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdfDocumento Reservadoapplication/pdf1047806https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/3/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdfc54a461b3c942267773842c0f5c220b4MD53embargoed access|||2420-09-11LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pngGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pngimage/png135270https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/4/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.png3c33bd14a529fb237a48e55516cbfa36MD54open accessGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdf.jpgGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdf.jpgIM Thumbnailimage/jpeg19529https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/5/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf.jpg76a6e57d702143ef4af5100ab73df7fdMD55open access20.500.12010/13162oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/131622020-09-11 10:20:50.265embargoed access|||2420-09-11Repositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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